You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR LIDOCAINE AND PRILOCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LIDOCAINE AND PRILOCAINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154167 ↗ Safety and Efficacy Study of NV-101 in Dental Patients Completed Novalar Pharmaceuticals, Inc. Phase 2 2003-02-01 The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101
NCT00355277 ↗ Local Anaesthetic Effects of Transcutaneous Amitriptyline Completed University Hospital, Clermont-Ferrand Phase 1 2005-11-01 The aim of this study is to assess the local anaesthetic effects of amitriptyline applied on the skin of human volunteers, considering the differential effects on mechanic and thermic sensitivity, the local and general tolerance, and the systemic absorption of the drug. The solution used for dilution of amitriptyline is the only one known to allow transcutaneous absorption of the drug [1]. Considering that the peripheral sensitive fibre is a possible site of action of tricyclic antidepressants for relieving neuropathic pain [2,3], this is a first step study before further assessment of the therapeutic effects of transcutaneous amitriptyline.
NCT00483990 ↗ Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers Completed Plethora Solutions Ltd Phase 1 2007-03-01 The main objective of the study is to determine the safety and tolerability of repeated application of PSD502 to the glans penis in healthy male volunteers
NCT00556478 ↗ Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation Completed Shionogi Inc. Phase 2/Phase 3 2007-10-01 The purpose of this study is to evaluate the effectiveness, safety and tolerability of the investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug, PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic (numbing) spray containing a mixture of lidocaine and prilocaine. The study drug will be applied in a spray to the penis prior to intercourse in order to decrease sensitivity in an attempt to delay ejaculation.
NCT00556478 ↗ Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation Completed Plethora Solutions Ltd Phase 2/Phase 3 2007-10-01 The purpose of this study is to evaluate the effectiveness, safety and tolerability of the investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug, PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic (numbing) spray containing a mixture of lidocaine and prilocaine. The study drug will be applied in a spray to the penis prior to intercourse in order to decrease sensitivity in an attempt to delay ejaculation.
NCT00808054 ↗ Evaluation of Analgesia With EMLA and Glucose Oral Solution Completed Federal University of Minas Gerais Phase 4 2008-11-01 In this randomized controlled study the investigators intended to compare analgesic effects of EMLA and/or oral glucose in 60 preterm neonate during arterial function and PICC installation.
NCT00808171 ↗ Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed Federal University of Minas Gerais Phase 4 2009-02-01 In this randomised controlled study the investigators intended to compare the analgesic effects of EMLA and\or nitrous oxide in children submitted to lumbar puncture.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LIDOCAINE AND PRILOCAINE

Condition Name

Condition Name for LIDOCAINE AND PRILOCAINE
Intervention Trials
Pain 12
Premature Ejaculation 4
Contraception 4
Anesthesia, Local 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LIDOCAINE AND PRILOCAINE
Intervention Trials
Premature Ejaculation 4
Hernia, Inguinal 3
Premature Birth 3
Pain, Postoperative 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LIDOCAINE AND PRILOCAINE

Trials by Country

Trials by Country for LIDOCAINE AND PRILOCAINE
Location Trials
United States 33
Egypt 8
France 5
Belgium 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LIDOCAINE AND PRILOCAINE
Location Trials
North Carolina 4
California 3
Utah 3
New York 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LIDOCAINE AND PRILOCAINE

Clinical Trial Phase

Clinical Trial Phase for LIDOCAINE AND PRILOCAINE
Clinical Trial Phase Trials
Phase 4 24
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LIDOCAINE AND PRILOCAINE
Clinical Trial Phase Trials
Completed 40
Unknown status 11
Not yet recruiting 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LIDOCAINE AND PRILOCAINE

Sponsor Name

Sponsor Name for LIDOCAINE AND PRILOCAINE
Sponsor Trials
Plethora Solutions Ltd 5
Cairo University 4
Assiut University 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LIDOCAINE AND PRILOCAINE
Sponsor Trials
Other 78
Industry 12
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.